Cargando…
A novel small compound TOIDC suppresses lipogenesis via SREBP1-dependent signaling to curb MAFLD
BACKGROUND: Inhibition of hepatic lipogenesis is widely regarded as an effective treatment for metabolic-associated fatty liver disease (MAFLD), although numerous related drugs have failed to reach clinical application. The goal of this study is to identify a novel small compound that can effectivel...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727880/ https://www.ncbi.nlm.nih.gov/pubmed/36474251 http://dx.doi.org/10.1186/s12986-022-00713-0 |